Short Interest in Vivani Medical, Inc. (NASDAQ:VANI) Decreases By 25.4%

Vivani Medical, Inc. (NASDAQ:VANI) saw a significant decline in short interest in February. As of February 27th, there was short interest totaling 290,597 shares, a decline of 25.4% from the February 12th total of 389,363 shares. Approximately 0.7% of the shares of the stock are short sold. Based on an average daily volume of 201,565 shares, the days-to-cover ratio is presently 1.4 days. Based on an average daily volume of 201,565 shares, the days-to-cover ratio is presently 1.4 days. Approximately 0.7% of the shares of the stock are short sold.

Insider Buying and Selling

In other news, Director Gregg Williams bought 1,351,351 shares of the stock in a transaction on Tuesday, January 27th. The shares were bought at an average price of $1.48 per share, with a total value of $1,999,999.48. Following the completion of the acquisition, the director owned 27,915,460 shares of the company’s stock, valued at approximately $41,314,880.80. This trade represents a 5.09% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders acquired 4,826,881 shares of company stock worth $5,962,104 in the last quarter. 46.40% of the stock is currently owned by insiders.

Institutional Trading of Vivani Medical

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Tudor Investment Corp ET AL purchased a new stake in shares of Vivani Medical in the fourth quarter valued at $1,127,000. Marshall Wace LLP purchased a new stake in Vivani Medical during the 4th quarter worth about $174,000. State Street Corp increased its position in Vivani Medical by 12.5% during the 4th quarter. State Street Corp now owns 144,865 shares of the company’s stock worth $178,000 after purchasing an additional 16,070 shares in the last quarter. Jane Street Group LLC acquired a new position in Vivani Medical in the 4th quarter valued at about $60,000. Finally, Renaissance Technologies LLC raised its stake in Vivani Medical by 118.4% in the 4th quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock valued at $121,000 after purchasing an additional 53,127 shares during the last quarter. 6.78% of the stock is currently owned by hedge funds and other institutional investors.

Vivani Medical Stock Performance

VANI stock opened at $1.10 on Friday. The stock’s 50 day moving average price is $1.28 and its 200 day moving average price is $1.36. The firm has a market cap of $85.99 million, a P/E ratio of -2.44 and a beta of 3.17. Vivani Medical has a 1 year low of $0.91 and a 1 year high of $1.92.

Wall Street Analysts Forecast Growth

VANI has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vivani Medical in a research note on Friday, January 9th. Wall Street Zen upgraded shares of Vivani Medical to a “sell” rating in a report on Saturday, November 22nd. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Vivani Medical has an average rating of “Hold” and a consensus target price of $4.00.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.